Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$620,000 |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$561M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
AmgenAMGN |
-$108M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Malabre Richard C | Jun 4, 2025 | Sell | 13,334 | $3.53 | $47,000 |
| Butler John P. | Mar 3, 2025 | Sell | 46,409 | $1.83 | $85,000 |
| Burke Steven Keith | Mar 3, 2025 | Sell | 7,144 | $1.83 | $13,000 |
| Butler John P. | Feb 3, 2025 | Sell | 97,982 | $2.1 | $210,000 |
| Butler John P. | Feb 3, 2025 | Sell | 46,268 | $2.1 | $97,000 |
| Burke Steven Keith | Feb 3, 2025 | Sell | 27,236 | $2.1 | $57,000 |
| Burke Steven Keith | Feb 3, 2025 | Sell | 23,270 | $2.1 | $49,000 |
| Malabre Richard C | Feb 3, 2025 | Sell | 30,202 | $2.1 | $63,000 |
| Grund Nicholas | Feb 3, 2025 | Sell | 55,621 | $2.1 | $120,000 |
| Hadas Nicole R. | May 13, 2024 | Sell | 12,016 | $1.26 | $15,000 |
| Dahan Michel | May 13, 2024 | Sell | 34,840 | $1.26 | $44,000 |
| Butler John P. | Feb 29, 2024 | Sell | 46,570 | $1.58 | $74,000 |
| Dahan Michel | Feb 29, 2024 | Sell | 8,661 | $1.58 | $14,000 |
| Hadas Nicole R. | Feb 29, 2024 | Sell | 5,974 | $1.58 | $9,400 |
| Burke Steven Keith | Feb 29, 2024 | Sell | 7,169 | $1.58 | $11,000 |
| Dahan Michel | Feb 27, 2024 | Sell | 10,744 | $1.52 | $16,000 |
| Butler John P. | Feb 27, 2024 | Sell | 37,733 | $1.52 | $57,000 |
| Hadas Nicole R. | Feb 27, 2024 | Sell | 7,411 | $1.52 | $11,000 |
| Burke Steven Keith | Feb 27, 2024 | Sell | 8,367 | $1.52 | $13,000 |
| Butler John P. | Feb 1, 2024 | Sell | 46,489 | $1.68 | $78,000 |
| Burke Steven Keith | Feb 1, 2024 | Sell | 24,311 | $1.68 | $41,000 |
| Burke Steven Keith | Aug 25, 2023 | Sell | 27,000 | $1.15 | $31,000 |
What's the latest insider transaction for Akebia Therapeutics?
The most recent insider transaction for Akebia Therapeutics was conducted by Malabre Richard C, who sold 13,334 shares on June 4, 2025 at a price of $3.53 per share.
Which insider has sold the most AKBA stock over the last two years?
Butler John P. has sold the most AKBA stock in the last 2 years, with a total value of $600,000.
What is the total value of insider transactions for Akebia Therapeutics (AKBA) in the last 2 years?
The total value of insider transactions for Akebia Therapeutics in the last 2 years is negative, amounting to -$1.1M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Akebia Therapeutics' market confidence?
Over the last 2 years, insider transactions for Akebia Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
